NL-OMON38562
Withdrawn
Not Applicable
SOM230 Graves Orbitopathy pilot trial - SOMGO
Overview
- Phase
- Not Applicable
- Status
- Withdrawn
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 12
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •\-moderate \* severe GO
- •\-corticosteroids contraindicated due to diabetes mellitus (see below), severe
- •osteoporosis, heart failure, psychosis, infectious diseases or other clinical relevant
- •comorbidities
- •\-corticosteroids refused by patients
- •\-age \> 18
Exclusion Criteria
- •\-inability/refusal to give informed consent
- •\-pregnancy
- •\-GO (dysthyroid optical neuropathy) necessitating high dose steroids or acute
- •decompression
- •\-abnormal thyroid function (defined as TSH \>4\.0 mU/l or FT4 \<10 or \>21 pmol/l)
- •\-pregnancy
- •\-drug abuse and smoking.
Investigators
Similar Trials
Recruiting
Not Applicable
Pilot study of SOM230 for Treatment of Graves’ OphthalmopathyDiseases of the eye and adnexaKCT0001645Yonsei University Health System, Severance Hospital20
Not yet recruiting
Not Applicable
SOM230 Graves Orbitopathy pilot trial.Graves OrbitopathyNL-OMON26944Academic Medical Center Amsterdam12
Active, not recruiting
Phase 1
Phase I trial: Ocular Technology Group International CV23-08The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.Not ApplicableISRCTN66819383CooperVision International Ltd40
Active, not recruiting
Phase 1
Phase I trial: Ocular Technology Group InternationalThe Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.Not ApplicableISRCTN90702227CooperVision International Limited20
Not yet recruiting
Phase 2
Sirolimus for Graves' Orbitopathy (GO)Graves OphthalmopathyNCT04598815University of Pisa54